Lineage Cell Therapeutics (LCTX) Accumulated Expenses (2011 - 2026)

Lineage Cell Therapeutics' Accumulated Expenses history runs 16 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 40.7% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (down 40.7% YoY), while the FY2025 annual figure was $3.7 million, up 22.11% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $1.2 million, down from $3.7 million in the prior quarter.
• The five-year high for Accumulated Expenses was $21.0 million in Q2 2022, with the low at $349000.0 in Q3 2023.
• The 5-year median for Accumulated Expenses is $1.9 million (2022), against an average of $2.9 million.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses surged 1474.21% in 2022, then tumbled 97.23% in 2023.
• Lineage Cell Therapeutics' Accumulated Expenses stood at $3.8 million in 2022, then dropped by 18.52% to $3.1 million in 2023, then declined by 1.83% to $3.1 million in 2024, then gained by 22.11% to $3.7 million in 2025, then slumped by 67.04% to $1.2 million in 2026.
• Business Quant data shows LCTX's Accumulated Expenses at $1.2 million in Q1 2026, $3.7 million in Q4 2025, and $486000.0 in Q3 2025.